Formulation Development
BASi & Seventh Wave Laboratories Combine Operations to Provide Broader Solutions & Greater Scientific Expertise to Clients
Bioanalytical Systems, Inc. and Seventh Wave Laboratories, LLC, recently announced they have signed an asset purchase agreement (APA) joining operations to provide broader solutions and…
ASLAN Pharmaceuticals Submits Clinical Trial Authorization Application
ASLAN Pharmaceuticals recently announced the submission of a clinical trial authorization application with the Singapore Health Sciences Authority (HSA) to initiate a Phase 1 trial…
Biologic Excipients Market Expected to be Valued at $1.7 Billion by End of 2028
Future Market Insights (FMI) delivers key insights on the global biologic excipients market in its upcoming report titled Biologic Excipients Market: Global Industry Analysis 2013–2017 and Opportunity Assessment…
Lonza Launches New Bioscience Website
Lonza Bioscience is inviting visitors to explore its new dedicated website: bioscience.lonza.com.
CrownBio Enters Partnership With Pierre Fabre to Accelerate Discovery & Development of Immuno-Oncology Agents
Crown Bioscience recently announced it has been selected by Pierre Fabre Research Institute as one of their partners to advance their immuno-oncology drug discovery pipeline.…
Atossa Genetics Completes All Dosing & Clinical Visits in its Study of Topical Endoxifen
Atossa Genetics Inc. recently announced it has completed dosing and clinical visits in its Phase 1 study of its proprietary topical Endoxifen in men. “We…
Celyad Doses First AML Patient at Final Dose Level in CYAD-01 THINK Trial & Begins Dosing First Patient With Second Cycle of Therapy
Celyad recently announced the first Acute Myeloid Leukemia (AML) patient was dosed with the first injections at the third and final dose level of CYAD-01…
Allena Pharmaceuticals Completes Animal Proof-of-Concept Study
Allena Pharmaceuticals, Inc. recently announced the completion of an animal proof-of-concept study supporting the selection of ALLN-346 as its lead product candidate for the treatment…
7 Hills Pharma Launches With $2-Million SBIR Grant & $4 Million in Seed Capital
7 Hills Pharma recently announced it has been awarded a $2-million Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH) titled…
Evonik Expands North American Contract Development & Manufacturing Capabilities for Advanced Injectables
Evonik recently announced a €35 million expansion of its contract development and manufacturing (CDMO) capabilities in North America to meet growing demand for controlled release injectable formulations. The expansion of the U.S. and Canadian facilities, which includes the installation of a new filling line, production facilities and analytical labs, will create more than 50 jobs.
Novacap to Expand its Pharmaceutical Offering in US With Major Acquisition
Novacap recently announced it has signed an agreement to acquire Boston-based PCI Synthesis, a leading US pharmaceutical contract development and manufacturing organization (CDMO), further reinforcing Novacap’s capabilities and offering for the pharmaceutical industry.
Epinephrine Nasal Spray in Development for Treatment of Anaphylaxis Shows Promise as Potential Alternative to Intramuscular Injection
INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that its investigational epinephrine nasal spray showed promise in an early clinical trial as a potential needle-free, non-invasive and easy-to-use alternative to intramuscular injection for the treatment of anaphylaxis.
Zealand Pharma Achieves Milestone in First Phase 3 Trial
Zealand Pharma A/S recently announced that the primary and key secondary objectives of the first multinational Phase 3 clinical trial of dasiglucagon for the treatment…
Paratek Presents New Analysis From Combined Phase 3 Skin Infection Studies
Paratek Pharmaceuticals, Inc. recently presented a new analysis of combined data from the company’s two, pivotal Phase 3 clinical studies of omadacycline in acute bacterial…
Nutriband Signs LOI to Acquire Carmel Biosciences
Nutriband Inc. recently announce it has signed a Letter of Intent to acquire 100% of Carmel Biosciences, a pharmaceutical company that addresses critical needs in…
Nkarta Therapeutics Announces Exclusive License to Natural Killer Cell Technology
Nkarta Therapeutics recently announced it has entered into a worldwide exclusive license agreement for proprietary Natural Killer cell engineering technology jointly owned by the National…
Avalon GloboCare Forms Joint Venture With Jiangsu Unicorn to Establish Provincial Network of Translational Cellular Therapy & Bio-Banking Programs
Avalon GloboCare Corp. recently announced it has formed a joint venture with Jiangsu Unicorn Biological Technology Co. Ltd, which brings extensive medical resources in Jiangsu…
FUJIFILM Cellular Dynamics Licenses University of California – Irvine’s Technologies
FUJIFILM Cellular Dynamics, Inc. (FCDI) recently announced it has entered into an exclusive patent license agreement with the University of California – Irvine (UCI) through its offices at UCI Applied Innovation to license and commercialize UCI’s technologies for derivation of microglia in the commercial research field and also a non-exclusive patent license agreement to commercialize microglia media formulation.
eFFECTOR Initiates Dosing of eFT508 in Phase 2 Expansion of Clinical Trial in Aggressive Form of Non-Hodgkin’s Lymphoma
eFFECTOR Therapeutics, Inc. recently announced that it has dosed the first patient in the Phase 2 expansion portion of its monotherapy trial of eFT508, the company’s oral, small molecule inhibitor of MNK1/2, for the treatment of relapsed, refractory non-germinal center B cell (non-GCB) diffuse large B cell lymphoma (DLBCL).
Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease From Oxford BioMedica; Announces Key Leadership Team Addition
Axovant Sciences recently announced that it has licensed the exclusive worldwide rights to develop and commercialize OXB-102, now AXO-Lenti-PD, from Oxford BioMedica. AXO-Lenti-PD is an investigational gene therapy for Parkinson’s disease that delivers three genes encoding a critical set of enzymes required for dopamine synthesis in the brain.
